Quick Answer
Tempest Therapeutics, Inc. reported Cash and Equivalents of $7.71 million for fiscal year 2025.
Tempest Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.71M | -74.5% |
| 2024 | $30.27M | -22.8% |
| 2023 | $39.23M | +25.6% |
| 2022 | $31.23M | -39.7% |
| 2021 | $51.83M | +175.4% |
| 2020 | $18.82M | -69.9% |
| 2019 | $62.48M | -14.7% |
| 2018 | $73.29M | +316.9% |
| 2017 | $17.58M | -60.0% |
| 2016 | $43.93M | +1.6% |
| 2015 | $43.22M | +573.9% |
| 2014 | $6.41M | -64.5% |
| 2013 | $18.08M | +22.3% |
| 2012 | $14.78M | +225.4% |
| 2011 | $4.54M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.51M | -66.0% | -47.4% |
| June 30, 2025 | $14.28M | -54.1% | -33.6% |
| March 31, 2025 | $21.51M | -33.5% | -28.9% |
| December 31, 2024 | $30.27M | -22.8% | +36.9% |
| September 30, 2024 | $22.12M | +98.9% | -28.9% |
| June 30, 2024 | $31.12M | +76.8% | -3.7% |
| March 31, 2024 | $32.33M | +41.0% | -17.6% |
| December 31, 2023 | $39.23M | +25.6% | +252.9% |
- Tempest Therapeutics, Inc. showed a decrease of -74.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Tempest Therapeutics, Inc.’s cash and equivalents has grown by 69.7% (from $4.54 million to $7.71 million).
- The most recent figure is from Tempest Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: